Graydon B Gereau, Diana Zhou, Kalynn J Van Voorhies, Ryan E Tyler, Jeffrey Campbell, Jackson G Murray, Ali Alvararez-Pamir, Luke Wykoff, Michel A Companion, Michael R Jackson, Steven H Olson, Lawrence S Barak, Lauren M Slosky, Ryan P Vetreno, Joyce Besheer, Zoe A McElligott
Alcohol use disorders (AUDs) impose an enormous societal and financial burden, and world-wide, alcohol misuse is the 7th leading cause of premature death1. Despite this, there are currently only 3 FDA approved pharmacological treatments for the treatment of AUDs in the United States. The neurotensin (Nts) system has long been implicated in modulating behaviors associated with alcohol misuse. Recently, a novel compound, SBI-553, that biases the action of Nts receptor 1 (NTSR1) activation, has shown promise in preclinical models of psychostimulant misuse...
April 13, 2024: bioRxiv